KRAS and lung cancer: Furthermore, considerable progress has been made in the development of targeted KRAS inhibitors in recent years, with two KRAS inhibitors already approved by the Food and Drug Administration for use in non–small cell lung cancer, and multiple others in clinical trials (75, 76).